Evidence Hub

Mucinous carcinoma of the breast: Rare histological entity to know: About two cases and review of literature

Bencherifi Y, Watik F, Lyafi Y, Mostapha B, Ennachit M, Mohammed EK

International journal of surgery case reports, 2023

3 citations

Abstract

Introduction and importance: Breast cancer is the first gynecological cancer in women, dominated by invasive ductal cancer . It is characterized by the presence of extracellular mucus, mucinous carcinoma represents one to 7 % of all invasive carcinomas and by a more favorable prognosis, Presentation of the case: We present two patients followed for an invasive mucinous carcinoma, CLINICAL DISCUSSION: Mucinous carcinoma of the breast is a rare entity. Therapeutic management does not differ from other histological types. It is based on surgery, chemotherapy and radiotherapy. Conservative treatment is recommended for T1, T2. Partial and accelerated irradiation of the breast is currently the most recommended after breast-conserving surgery.

Conclusion: Mucinous carcinoma is a rare histological entity with a favorable prognosis compared to other histological types. A benign-looking mass on imaging is not always reassuring, especially if it occurs in a woman over 60 years old. Since it can reveal colloid carcinoma.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free